简体中文

Press releases

14 Apr 2025

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions

Read article
26 Feb 2025

CORXEL Bolsters Leadership Team with Seasoned CFO Kevin Xie to Drive Next Phase of Company Growth

Read article
20 Feb 2025

CORXEL Announces China National Medical Products Administration Approval of the Clinical Trial Application for ORION, the Global Registrational Study of JX10 in Patients with Acute Ischemic Stroke

Read article
22 Jan 2025

CORXEL Announces Upcoming Presentation at the International Stroke Conference 2025 on JX10 Improving Neurological Outcomes in Acute Lacunar Infarct

Read article
17 Jan 2025

CORXEL Announces NMPA Acceptance of New Drug Application for Etripamil

Read article
23 Dec 2024

CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes

Read article
20 Dec 2024

CORXEL and Sanofi Announce an Agreement for Aficamten in Greater China Markets

Read article
Load more

Developing innovative cardiometabolic therapies globally

Copyright © 2025 CORXEL. All Rights Reserved.
Designed & built by SampsonMay

沪ICP备20017872号-3

沪公网安备31010602008424号